Grifols News and Biopharmaceuticals & Plasma Medicines Updates

10.07
0.260
2.65 %
Daily range
Weekly range
  • Mykhailo Ihnatenko
  • 28.08.2026
Grifols holds near €10 as investors reassess turnaround
​Grifols remains in a re-rating phase following its July earnings report, with a strong breakout from a six-month consolidation giving way to more cautious trading around €10.Following the H1 ...
  • Mykhailo Ihnatenko
  • 19.06.2026
Grifols launches FESILTY as investors weigh growth against debt concerns
Grifols shares remain in focus following the launch of its new drug FESILTY in the United States. However, as before, the key factor in evaluating the company is not only business growth but also ...
  • Mykhailo Ihnatenko
  • 10.06.2026
Grifols recovery hinges on debt reduction
​Grifols shares remain under pressure following a challenging two-year period, although the company's fundamental outlook is gradually improving. The business continues to grow earnings while ...